Welcome to our dedicated page for AURORA SPINE news (Ticker: ASAPF), a resource for investors and traders seeking the latest updates and insights on AURORA SPINE stock.
Aurora Spine Corp (ASAPF) is a pioneering company in the spinal implant market, focusing on innovative, minimally invasive, and regenerative spinal implant technologies. Recently, the company introduced Ghost Tube™, a groundbreaking product designed for superior anchoring during surgical procedures. With a translucent thermoplastic body and non-slipping titanium anchors, Ghost Tube™ ensures stable surgical access without obstructing x-ray visibility. President & CEO, Trent Northcutt, expressed enthusiasm for the newly received patent, emphasizing its support for the SiLO TFX SI Fusion System and the development of future radiolucent tools. Chief Technology Officer, Laszlo Garamszegi, highlighted the company's commitment to disruptive and innovative technologies, aiming to enhance patient care and outcomes. Aurora Spine continues to expand its product and intellectual property portfolio, striving to deliver efficient solutions and improve treatment options.
Aurora Spine Corporation (OTCQB: ASAPF) has been awarded the 2022 Annual Spine Technology Award for its innovative DEXA Technology™ Bone Density-Matched Interbody Implants. Recognized by RRY Publications LLC and Orthopedics this Week, this technology adjusts spinal implants to match patients’ bone density, enhancing surgical outcomes. The award will be presented at the 37th Annual Meeting of the North American Spine Society in Chicago. Aurora Spine emphasizes that DEXA Technology™ represents a significant advancement in spinal implants, merging conventional machining, 3D printing, and additive manufacturing.
Aurora Spine Corporation (OTCQB: ASAPF) has received FDA 510(k) clearance for its SiLO TFX MIS Sacroiliac Joint Fixation System. This patented device is designed to enhance patient outcomes in spinal surgery through minimally invasive techniques. A detailed announcement regarding this system is expected on October 6, 2022. The clearance is a significant milestone for Aurora Spine, as it underscores the company's commitment to advancing spinal care technology.
Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) announced its participation in the Lytham Partners Fall 2022 Investor Conference on September 28-29, 2022. The company will present a panel discussion titled Simplifying the Complex, featuring CEO Trent Northcutt and Clinical Education Director Krissy Ramey, available at 9:00 AM ET on September 28. Virtual 1x1 meetings with management will also be conducted. Aurora Spine focuses on innovative spinal implant technologies aimed at improving surgical outcomes, with more information available on their website.
Aurora Spine Corporation reported record quarterly revenue of $4.1 million for Q2 2022, marking a 68% year-over-year increase and 15% sequential growth from Q1. The company achieved positive EBITDAC of $96,285 compared to losses in previous quarters. Key highlights include receiving FDA clearances for the ZIP™ family of implants and the DEXA SOLO-L™ spinal fusion system, along with the issuance of a new patent for ZIPFlex™ Technology. The gross margin improved to 52.6%, reflecting successful sales strategies and increased use of proprietary products.
Aurora Spine Corporation (TSXV: ASG; OTCQB: ASAPF) has announced it will release its financial results for the second quarter ended June 30, 2022, on August 29, 2022. The management will host a conference call that same day at 11:00 a.m. Eastern Time to discuss the results. Interested parties can access the call via phone or a live webcast. Aurora Spine is dedicated to developing innovative medical devices aimed at improving spinal surgery outcomes. The company urges caution regarding forward-looking statements, as actual results may vary significantly due to various risks and uncertainties.
Aurora Spine Corporation (OTCQB: ASAPF) announced FDA clearance for its ZIP™ series of minimally invasive spinal implants to treat Lumbar Spinal Stenosis, expanding its indications beyond degenerative disc disease and spondylolisthesis. This new indication aims to address a growing patient population, estimated to increase by 18 million over the next decade. The ZIP device features a patented one-step locking mechanism, reducing surgery time and recovery. CEO Trent Northcutt highlighted this achievement as a key milestone for Aurora, enhancing patient care options while supporting the company's growth strategy.
Aurora Spine Corporation (ASAPF) recently announced the issuance of United States Patent No: 11,331,199 for its ZIPFlex™ Technology. This patent covers a minimally invasive interlaminar implant designed for motion preservation and fusion in spinal surgeries. The ZIPFlex device allows surgeons to perform motion preservation operations or convert to fusion procedures as necessary. This innovation could enhance treatment options for patients suffering from lumbar spinal degenerative diseases. The company emphasizes its focus on simplifying complex surgical solutions for improved patient outcomes.
Aurora Spine Corporation (ASAPF) announced FDA 510(k) clearance for its innovative DEXA SOLO-L spinal fusion system, a first-of-its-kind 3D printed standalone ALIF device tailored to match patients' bone density. This development enhances Aurora's DEXA Technology Platform, marking a significant advancement in spinal surgery by personalizing implants. The CEO, Trent Northcutt, emphasized the potential for increased sales and surgeon adoption. This approval follows the company's commitment to innovation and expands their product range, previously including the DEXA-C cervical implant.
Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) will release its financial results for Q1 2022 on May 23, 2022. This will be followed by a conference call scheduled for May 24, 2022, at 11:00 a.m. ET to discuss the results. The call can be accessed via phone at (844) 861-5497 or through a live webcast. A replay will be available until May 31, 2022. Aurora Spine specializes in designing innovative spinal implant technologies aimed at enhancing surgical outcomes.
Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) announced it will release its financial results for Q4 2021 on April 29, 2022. A conference call is scheduled for May 2, 2022, at 11:00 a.m. ET to discuss these results. The call can be accessed by phone or via webcast. Aurora Spine specializes in innovative medical devices aimed at enhancing spinal surgery outcomes and is focused on minimally invasive technologies.
FAQ
What is the current stock price of AURORA SPINE (ASAPF)?
What is the market cap of AURORA SPINE (ASAPF)?
What is Aurora Spine Corp known for?
What is Ghost Tube™ and its significance?
Who are the key figures at Aurora Spine Corp?
What recent achievements has Aurora Spine Corp celebrated?
How does Aurora Spine Corp contribute to the healthcare industry?
What is the vision of Aurora Spine Corp for the future?
Where can I find more information about Aurora Spine Corp?
How can investors get in touch with Aurora Spine Corp?
What sets Aurora Spine Corp apart from its competitors?
What are the core values of Aurora Spine Corp?
